Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

Smokers Clinical Trial

Official title:

A Two-arm, Open Label, Prefatory Study to Explore Changes in Nasal Mucociliary Clearance Between Smokers and Never Smokers and to Standardize Nasal Scraping Procedure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03086707
• Other study ID #: P1-CMS-01-US
• Status: Completed
• Phase: N/A
• Start date: January 21, 2017
• Est. completion date: September 29, 2017

Study information

• Verified date: October 2020
• Source: Philip Morris Products S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study intends to evaluate the nasal mucociliary clearance (NMC) by determining the value obtained for saccharin transit time (STT) test over the course of 12 hours following a single cigarette use in adult smokers, to compare it relative to never smokers, and to examine the relationship between plasma nicotine levels and STT value in smokers and never smokers. Safety will also be monitored during the study.

The planned maximum study duration for a single study participant from Screening through completion of study will be 33 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: September 29, 2017
• Est. primary completion date: August 14, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 25 Years to 45 Years

Eligibility

Inclusion Criteria to be met at Visit 1 and Visit 2:

• Male smokers aged =25 to =45 years old.

• Male never smokers aged =25 to =45 years old.

• Subject's BMI is comprised between 18.0 kg/m2 to 32.0 kg/m2, inclusive.

• Subject is healthy, as judged by the Investigator.

Additional Inclusion Criteria to allocate subjects in one of the two groups:

• Non-menthol cigarette smokers:

• A positive urine cotinine test (=200 ng/mL).

• Smoked at least 20 cigarettes per day for at least the past 5 years.

• eCO levels >10 parts per million (ppm).

• No plans to quit smoking in the next 3 months.

• Never smokers:

• Subject who has smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.

• A negative urine cotinine test (<200 ng/mL).

• eCO levels = 5 ppm.

Exclusion Criteria:

• As per the Investigator's judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).

• Inability to taste sweet within 60 minutes in the STT test.

• Any condition the Principal Investigator or designee has cause to believe would interfere with the procedures for upper or lower airway function. This could include, but is not limited to, nasal/septum deviations, or nasal polyps or nasal allergies.

Related Conditions & MeSH terms

• Never Smokers
• Smokers

Intervention

Other:
• Cigarette
After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.

Locations

Country	Name	City	State
United States	Inflamax Research - Neptune	Neptune	New Jersey
United States	Inflamax Research - Newark	Newark	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Philip Morris Products S.A.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006 Jan 31;7:3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Saccharin Transit Time at t0, Start of Product Use	Before performing the test, each subject will spend approximately 15 minutes acclimatizing to the environment of the clinic. A 1-2 mm particle of saccharin will be placed under direct vision, approximately 1 cm behind the anterior end of the inferior turbinate. The position of the subject's head should be flexed approximately 10° by visual assessment.; The saccharin transit time will be determined as the elapsed time in minutes and seconds from placement of the saccharin until the time the subject perceives a sweet taste.	Baseline
Primary	Saccharin Transit Time 4 Hours After Product Use	Before performing the test, each subject will spend approximately 15 minutes acclimatizing to the environment of the clinic. A 1-2 mm particle of saccharin will be placed under direct vision, approximately 1 cm behind the anterior end of the inferior turbinate. The position of the subject's head should be flexed approximately 10° by visual assessment.; The saccharin transit time will be determined as the elapsed time in minutes and seconds from placement of the saccharin until the time the subject perceives a sweet taste.	Measured at 4 hours after product use.
Primary	Saccharin Transit Time 8 Hours After Product Use	Before performing the test, each subject will spend approximately 15 minutes acclimatizing to the environment of the clinic. A 1-2 mm particle of saccharin will be placed under direct vision, approximately 1 cm behind the anterior end of the inferior turbinate. The position of the subject's head should be flexed approximately 10° by visual assessment.; The saccharin transit time will be determined as the elapsed time in minutes and seconds from placement of the saccharin until the time the subject perceives a sweet taste.	Measured at 8 hours after product use.
Primary	Saccharin Transit Time 12 Hours After Product Use	Before performing the test, each subject will spend approximately 15 minutes acclimatizing to the environment of the clinic. A 1-2 mm particle of saccharin will be placed under direct vision, approximately 1 cm behind the anterior end of the inferior turbinate. The position of the subject's head should be flexed approximately 10° by visual assessment.; The saccharin transit time will be determined as the elapsed time in minutes and seconds from placement of the saccharin until the time the subject perceives a sweet taste.	Measured at 12 hours after product use.
Primary	Concentration of Plasma Nicotine at t0, Start of Product Use	Nicotine plasma concentrations will be measured using validated LC/MS/MS bioanalytical method.	Baseline
Primary	Concentration of Plasma Nicotine 4 Hours After Product Use	Nicotine plasma concentrations will be measured using validated LC/MS/MS bioanalytical method.	Measured at 4 hours after product use.
Primary	Concentration of Plasma Nicotine 8 Hours After Product Use	Nicotine plasma concentrations will be measured using validated LC/MS/MS bioanalytical method.	Measured at 8 hours after product use.
Primary	Concentration of Plasma Nicotine 12 Hours After Product Use	The Nicotine plasma concentrations will be measured using validated LC/MS/MS bioanalytical method.	Measured at 12 hours after product use.
Secondary	Ribonucleic Acid Quantity (Right Nostril)	Ribonucleic Acid quantity: concentration measured in the right nostril (RNA protect buffer) using two nasal scraping methods	Nasal scraping was performed at the final clinic visit, on Day 2, before checkout from the study.
Secondary	Ribonucleic Acid Quantity (Left Nostril)	Ribonucleic Acid quantity: concentration measured in the left nostril (Qiazol buffer) using two nasal scraping methods	Nasal scraping was performed at the final clinic visit, on Day 2, before checkout from the study.
Secondary	Ribonucleic Acid Quality (Right Nostril)	Ribonucleic Acid quality assessed using the RNA integrity number: measured in the right nostril (RNA protect buffer) using two nasal scraping methods. RNA integrity Number is an algorithm for assessing RNA integrity and based on a numbering system from 1 to 10, with 1 being the most degraded profile and 10 being the most intact.	Nasal scraping was performed at the final clinic visit, on Day 2, before checkout from the study.
Secondary	Ribonucleic Acid Quality (Left Nostril)	Ribonucleic Acid quality assessed using the RNA integrity number: measured in the left nostril (Qiazol buffer) using two nasal scraping methods. RNA integrity Number is an algorithm for assessing RNA integrity and based on a numbering system from 1 to 10, with 1 being the most degraded profile and 10 being the most intact.	Nasal scraping was performed at the final clinic visit, on Day 2, before checkout from the study.